Benjamin Caplin

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2176328/benjamin-caplin-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55	1,960	22	44
papers	citations	h-index	g-index
67	3,208 ext. citations	8	5.12
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
55	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial <i>Lancet, The</i> , 2022 , 399, 665-676	40	43
54	Acquired Chronic Tubulointerstitial Nephritis 2022, 599-609		
53	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 1419-1426	35.1	36
52	"Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.". <i>Epigenetics</i> , 2021 , 16, 718-728	5.7	3
51	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 1637-1645	40	537
50	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 2049-2059	40	157
49	Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1237-1246	6.9	7
48	Feasibility of evaluation of the natural history of kidney disease in the general population using electronic healthcare records. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1603-1609	4.5	0
47	CKD and CKDu in northern Peru: a cross-sectional analysis under the DEGREE protocol. <i>BMC Nephrology</i> , 2021 , 22, 37	2.7	1
46	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 605-612	40	117
45	Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty. <i>Journal of Nephrology</i> , 2021 , 34, 315-323	4.8	6
44	Prevalence and risk factors for chronic kidney disease of unknown cause in Malawi: a cross-sectional analysis in a rural and urban population. <i>BMC Nephrology</i> , 2020 , 21, 387	2.7	4
43	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. <i>BMJ Open</i> , 2020 , 10, e033923	3	
42	Identification of young adults at risk of an accelerated loss of kidney function in an area affected by Mesoamerican nephropathy. <i>BMC Nephrology</i> , 2019 , 20, 21	2.7	3
41	Prevalence and risk factors for impaired kidney function in the district of Anuradhapura, Sri Lanka: a cross-sectional population-representative survey in those at risk of chronic kidney disease of unknown aetiology. <i>BMC Public Health</i> , 2019 , 19, 763	4.1	17
40	Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. <i>BMJ Open</i> , 2019 , 9, e023353	3	17
39	A histopathological comparison of pulpal response to formocresol and sodium hypochlorite used as pulpotomy medicaments: In primary teeth - A clinical trialA histopathological comparison of pulpal response to formocresol and sodium hypochlorite used as pulpotomy medicaments: In primary	0.6	4

38	Chronic kidney disease of undetermined aetiology: tens of thousands of premature deaths, yet too much remains unknown. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1839-1841	4.3	1
37	Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). <i>BMJ Open</i> , 2019 , 9, e031169	3	8
36	Environmental exposures in young adults with declining kidney function in a population at risk of Mesoamerican nephropathy. <i>Occupational and Environmental Medicine</i> , 2019 , 76, 920-926	2.1	14
35	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. <i>Kidney International</i> , 2018 , 93, 1432-1441	9.9	27
34	Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data. <i>British Journal of General Practice</i> , 2018 , 68, e512-e523	1.6	14
33	How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1373-1379	4.3	17
32	What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 496-506	4.5	46
31	Decline in Kidney Function among Apparently Healthy Young Adults at Risk of Mesoamerican Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2200-2212	12.7	39
30	FP366OUTCOMES OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGES 3-5 MANAGED IN PRIMARY CARE IN THE UK - FINDINGS FROM THE NATIONAL CKD AUDIT. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i155-i155	4.3	
29	Galactosylation of IgA1 Is Associated with Common Variation in. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2158-2166	12.7	65
28	Rationale, description and baseline findings of a community-based prospective cohort study of kidney function amongst the young rural population of Northwest Nicaragua. <i>BMC Nephrology</i> , 2017 , 18, 16	2.7	12
27	Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, ii151-ii158	4.3	3
26	Urinary biomarkers of tubular injury in chronic kidney disease. <i>Kidney International</i> , 2017 , 91, 21-23	9.9	9
25	International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE). <i>BMC Nephrology</i> , 2017 , 18, 1	2.7	62
24	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 185	5-9953	33
23	Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models. <i>Cardiovascular Endocrinology</i> , 2017 , 6, 120-127		4
22	MP313IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i443-i443	4.3	
21	Infection Rates Following Buttonhole Cannulation in Hemodialysis Patients. <i>Therapeutic Apheresis</i> and Dialysis, 2016 , 20, 476-482	1.9	13

20	Peritoneal protein clearance rather than faster transport status determines outcomes in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2015 , 35, 216-21	2.8	34
19	Dimethylarginine dimethylaminohydrolase 2 regulates nitric oxide synthesis and hemodynamics and determines outcome in polymicrobial sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1382-92	9.4	29
18	Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 3045-59	12.7	25
17	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1185-92	4.3	69
16	CME Renal medicine (100621): self-assessment questionnaire. Clinical Medicine, 2015, 15, 589-590	1.9	78
15	SP847THE USE OF mTORI IN PATIENTS WITH RECURRENT CMV INFECTION AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii656-iii657	4.3	
14	Assessment of the Renal Patient 2014 , 1-17		
13	Chronic Kidney Disease: Cardiovascular Complications 2014 , 589-601		
12	Does online haemodiafiltration reduce intra-dialytic patient symptoms?. <i>Nephron Clinical Practice</i> , 2013 , 124, 184-90		14
11	Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function. <i>Clinical Transplantation</i> , 2013 , 27, E669-78	3.8	4
10	Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2012 , 32, 2892-900	9.4	60
9	Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 1343-53	9.4	75
8	PatientsRperspective of haemodialysis-associated symptoms. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2656-63	4.3	113
7	Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. <i>Kidney International</i> , 2010 , 77, 459-67	9.9	22
6	RENAL DISEASE IS ASSOCIATED WITH ACCELERATED VASCULAR AGEING: INITIAL RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION: 8A.02. <i>Journal of Hypertension</i> , 2010 , 28, e417	1.9	3
5	Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. <i>Transplantation</i> , 2009 , 87, 852-6	1.8	22
4	Arterial calcification in dialysis patients and transplant recipients. <i>Seminars in Dialysis</i> , 2007 , 20, 144-9	2.5	15
3	Antiviral treatment after solid organ transplantation. <i>Lancet, The</i> , 2005 , 366, 806-7; author reply 807	40	7

LIST OF PUBLICATIONS

Dinucleotide repeat polymorphism at the HOX 2B locus. Human Molecular Genetics, 1992, 1, 218 2 4

5.6

Severity of COVID-19 after Vaccination among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN,CJN.16621221

6.9